> ## Content Index > Fetch the complete content index at: https://compoundcodex.org/llms.txt > Use this file to discover other available public pages before exploring further. # Omega-3 for triglycerides - URL: https://compoundcodex.org/omega-3-triglycerides/ - Published: 2026-08-22T06:35:08.000Z - Updated: 2026-08-24T08:07:13.000Z - Description: Does omega-3 lower triglycerides — and does that translate into fewer heart attacks? - Author: The Archivist - Tags: supplements, grade-strong, verdict-supported, omega-3 Strong evidence Supported ⚑ Identified in trials Marks reviewed Aug 2026 4 sources cited Next review Aug 2027 --- ## The rare case where someone ran the outcome trial Three times now this site has described the same shape: a supplement moves a number in a blood test, and nobody ever checked whether the person got healthier. NAD+ rose. Growth hormone rose. Cortisol fell. In each case the downstream question went unasked. Omega-3 is the exception. It lowers triglycerides — reliably, at a known dose, confirmed well enough that regulators approved prescription drugs for the purpose. And then two enormous randomised trials were run to find out whether that translated into fewer cardiovascular events. They came back disagreeing with each other, and the argument about why is one of the more instructive fights in modern cardiology. ## The settled part: triglycerides The American Heart Association's 2019 science advisory is the authoritative synthesis.[1](#c1) At a prescription dose of 4 g/day, omega-3 lowers triglycerides substantially, and the advisory concludes plainly that these agents "are an effective and safe option for reducing triglycerides as monotherapy or as an adjunct to other lipid-lowering agents." #### Prescription omega-3 at 4 g/day — AHA science advisory Triglyceride reduction, very high triglycerides (≥500 mg/dL) ≥30% LDL-C with EPA+DHA agents, very high triglycerides concurrent increase LDL-C with EPA-only, very high triglycerides no increase In hypertriglyceridemia (200–499 mg/dL), either formulation comparable, no LDL-C rise Non-HDL-C and apolipoprotein B in the largest trials modestly decreased Note the second row, because it is the kind of detail that disappears from summaries. In people with *very* high triglycerides, the EPA+DHA formulations lower triglycerides while **raising LDL cholesterol at the same time**. EPA-only formulations do not.[1](#c1) Two products described interchangeably as "omega-3" behave differently on the lipid panel. ## The dose in the trials is not the dose in the bottle Everything above refers to **4 grams per day of prescription omega-3** — more than 3 g/day of combined EPA+DHA.[1](#c1) A typical over-the-counter fish oil softgel labelled "1000 mg" contains roughly 300 mg of actual EPA+DHA; the rest is other fats. Reaching the studied dose from those capsules means taking something on the order of a dozen a day, every day. This is the **"check it's the same thing"** habit, which we named while writing about TB-500 and which applies just as sharply to a product sold in every pharmacy. The trials establishing that omega-3 lowers triglycerides used a prescription drug at a pharmacological dose. A two-capsule daily habit is not a smaller version of that intervention — it is a different one, and it has not been shown to do what the 4 g/day trials showed. ## The bigger question, and the two trials that split on it Lowering triglycerides is only interesting if it prevents something. Two large, well-conducted, industry-funded trials tested exactly that, and reached opposite conclusions. REDUCE-IT · 2019 · positive Agenticosapent ethyl (EPA only) Dose4 g/day Comparatormineral oil Participants8,179 Follow-upmedian 4.9 years Primary endpoint17.2% vs 22.0% HR 0.75 (0.68–0.83) P<0.001 Cardiovascular death4.3% vs 5.2% HR 0.80, P=0.03 FunderAmarin Pharma STRENGTH · 2020 · null Agentomega-3 CA (EPA + DHA) Dose4 g/day Comparatorcorn oil Participants13,078 Follow-uphalted early for futility Primary endpoint12.0% vs 12.2% HR 0.99 (0.90–1.09) P=0.84 GI adverse events24.7% vs 14.7% FunderAstraZeneca REDUCE-IT found a 25% relative reduction in major cardiovascular events over nearly five years — a large effect, in 8,179 people, on hard clinical endpoints.[2](#c2) STRENGTH enrolled 13,078 people at 675 sites in 22 countries and was **stopped early because an interim analysis showed a low probability of benefit**. Its hazard ratio was 0.99.[3](#c3) > These findings do not support use of this omega-3 fatty acid formulation to reduce major adverse cardiovascular events in high-risk patients. Nicholls et al., JAMA, 2020[3](#c3) ## Why they disagree — three candidate explanations A 2024 analysis in *Frontiers in Nutrition* lays out the leading accounts, and none of them has settled the matter.[4](#c4) #### The competing explanations **The comparator was not inert.** REDUCE-IT's mineral oil arm saw hs-CRP rise from 2.1 to 2.8 mg/L by year two — a 33% increase. Mineral oil may interfere with absorption of statins and fat-soluble vitamins. would inflate the benefit **The comparator was actively good.** STRENGTH's corn oil is rich in linoleic acid, and polyunsaturated fat intake is itself associated with lower cardiovascular event rates. would mask a benefit **EPA levels never got high enough.** REDUCE-IT achieved plasma EPA of 144.0 µg/mL on purified EPA; STRENGTH reached 89.6 µg/mL on the EPA+DHA formulation. threshold effect Read those together and the honest position becomes obvious. The first explanation says REDUCE-IT overstated the benefit because its control arm was harmed. The second says STRENGTH understated it because its control arm was helped. The third says the two trials never tested the same exposure. Each is plausible. They cannot all be the main reason, and no trial has yet been run that would separate them. One detail of timing is worth noticing. The AHA advisory, published in 2019, cited REDUCE-IT's 25% reduction as support for using omega-3 to reduce cardiovascular risk — and noted that "the results of a trial of 4 g/d prescription EPA+DHA in hypertriglyceridemia are anticipated in 2020."[1](#c1) That anticipated trial was STRENGTH. It came back null. You can watch a field's expectation get written down and then fail, in the space of eighteen months. ## Why the cardiovascular claim is Mixed 1. **Does a meta-analysis decide it?** Pooled analyses exist but they inherit the same conflict; the disagreement is between two individual trials large enough that neither is outweighed by the other. → Does not resolve 2. **Weight by size and quality.** Both are large, multicentre, double-blind and well conducted. STRENGTH is larger; REDUCE-IT ran longer. Both were funded by the manufacturer of the agent tested. There is no quality argument that cleanly favours one. → Does not resolve 3. **Does a variable explain the split?** Three candidates — comparator oil, formulation, achieved EPA level — each with support and none demonstrated. Under our rule a candidate explanation is not an established one. → Candidates only 4. **The conflict stands.** Verdict Mixed; strength capped at Moderate despite more than 21,000 pooled participants. → Moderate · Mixed ## Two claims, two answers Lowers triglycerides at prescription dose (4 g/day) Strong Supported Reduces major adverse cardiovascular events Moderate Mixed Both claims concern **prescription omega-3 at 4 g/day**. Neither should be read as a finding about over-the-counter fish oil at typical supplement doses, which these trials did not test. ## Safety and unknowns - Adverse events reported REDUCE-IT found a higher rate of hospitalisation for atrial fibrillation or flutter in the treatment arm — **3.1% versus 2.1%, P=0.004** — and serious bleeding events in 2.7% versus 2.1% (P=0.06).[2](#c2) STRENGTH found gastrointestinal adverse events in 24.7% of the omega-3 group versus 14.7% on corn oil.[3](#c3) - Longest human exposure studied Median 4.9 years in REDUCE-IT.[2](#c2) This is among the best-characterised long-term exposures of anything on this site. - Known interactions and at-risk groups The atrial fibrillation signal is the one to raise with a clinician, particularly for anyone with existing arrhythmia or on anticoagulants given the bleeding trend. In very high triglycerides, EPA+DHA formulations raise LDL-C while lowering triglycerides.[1](#c1) - Regulatory status Prescription omega-3 formulations are FDA-approved for treating very high triglycerides.[1](#c1) Over-the-counter fish oil is sold as a dietary supplement and is a different product at a different dose. - What has not been characterized Whether over-the-counter doses do anything comparable. Which of the three explanations for the REDUCE-IT/STRENGTH split is correct — resolving it would require a trial with a genuinely neutral comparator that nobody has yet run. Whether EPA-only and EPA+DHA differ in cardiovascular effect, or only in the trials that happened to test them. ## How this was graded #### Evidence strength — Strong (triglyceride claim), criteria checked Qualifying randomized controlled trialsmany, synthesised by AHA advisory ✓ Trials with 100+ participants eachREDUCE-IT 8,179 · STRENGTH 13,078 ✓ Independent research groupsmultiple, different sponsors ✓ Total participants\>21,000 in the two outcome trials alone ✓ Authoritative synthesisAHA science advisory ✓ Replication across populations22 countries, 675 sites in STRENGTH ✓ Verdict is not MixedSupported, for triglycerides ✓ The triglyceride claim reaches Strong on the first route to scale — several trials of 100+ participants — rather than on the many-small-trials route that creatine and caffeine used. Note that the *same evidence base* yields Strong for the lipid effect and Moderate/Mixed for the clinical outcome. That is not inconsistency; it is two different questions asked of the same trials. ## Bottom line Prescription omega-3 at 4 g/day lowers triglycerides by 30% or more. That is settled, and it is why these are approved drugs rather than merely supplements. Whether that prevents heart attacks is genuinely unresolved. One 8,179-person trial found a 25% reduction in major cardiovascular events. A 13,078-person trial was stopped early for futility with a hazard ratio of 0.99\. The three leading explanations for the gap — a harmful placebo, a beneficial placebo, and a formulation that never reached the necessary EPA level — are all plausible and none is established. And none of it describes the fish oil in your cupboard. The dose that produced these findings is roughly a dozen typical capsules a day, which is not what anyone is taking. supplements grade-strong verdict-supported omega-3 ## Sources 1. Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. *Circulation*. 2019;140(12):e673–e691\. [PMID 31422671](https://pubmed.ncbi.nlm.nih.gov/31422671/?ref=compoundcodex.org) 2. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *New England Journal of Medicine*. 2019;380(1):11–22\. REDUCE-IT, NCT01492361; funded by Amarin Pharma. [PMID 30415628](https://pubmed.ncbi.nlm.nih.gov/30415628/?ref=compoundcodex.org) 3. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. *JAMA*. 2020;324(22):2268–2280\. NCT02104817\. [PMID 33190147](https://pubmed.ncbi.nlm.nih.gov/33190147/?ref=compoundcodex.org) 4. Zhang W, Gan D, Huo S, Chen P. Unraveling the discrepancies between REDUCE-IT and STRENGTH trials with omega-3 fatty acids: new analytical approaches. *Frontiers in Nutrition*. 2024;11:1490953\. [PMC11697285](https://pmc.ncbi.nlm.nih.gov/articles/PMC11697285/?ref=compoundcodex.org) **The Compound Codex** — every mark on this page is assigned under our [public editorial standards](https://compoundcodex.org/editorial-standards/). The rubric is versioned, its revisions are logged, and any grade here is open to challenge. This breakdown summarizes published research for informational purposes only. It is not medical advice and does not endorse the use of any compound discussed. Doses mentioned describe the protocols used in cited trials and are not recommendations. Prescription omega-3 is a medication; if you have high triglycerides that is a conversation for the clinician managing your lipids, not a supplement aisle decision. © 2026 The Compound Codex · Every claim cited, none of them prescriptive.